LOGIN  |  REGISTER
Recursion
C4 Therapeutics

Avanos Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 06, 2025 | Last Trade: US$15.86 0.34 -2.10

ALPHARETTA, Ga., Jan. 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, interim chief executive officer, will present at the 43rd  Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, Jan. 13, at approximately 3:45 p.m. PST.

A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site.

About Avanos Medical, Inc. 

Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, we are committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. We develop, manufacture and market our recognized brands globally and hold leading market positions in multiple categories across our portfolio. For more information, visit Avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page